Phase 3 menstrual bleeding profile data for segesterone acetate and ethinyl estradiol vaginal system (Annovera)

Results pooled from 2 identically designed, open-label Phase 3 trials (n=2070) of Annovera, a long-lasting, reversible contraceptive for women of reproductive age showed daily avg of 94.8% to 97.6% of women reported no unscheduled bleeding per cycle when used for up to 13 cycles

Source:

Biospace Inc.